<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): December 10, 2008</B>

<P style="font-size: 24pt" align="center"><B>POLYMEDIX, INC.<BR>
</B><FONT
style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>000-51895</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>27-0125925</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>170 N. Radnor Chester Road,
Suite 300<BR>
Radnor, Pennsylvania<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>19087</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(448) 598-2400</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>Not
Applicable<BR>
</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="15%">&nbsp;</TD>
  <TD width="85">&nbsp;</TD>
 </TR>
<!-- End Table Head -->

<!-- Begin Table Body -->

 <TR valign="bottom">
  <TD valign="top" align="left"><B>Item&nbsp;7.01.</B></TD>
  <TD align="left"><B>Regulation&nbsp;FD Disclosure.</B></TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD align="left"> On December&nbsp;10, 2008, PolyMedix, Inc. presented a slide
presentation at its special meeting of stockholders entitled
&#8220;Presentation of Phase IA PMX-30063 Clinical Results&#8221;. A copy of
the presentation is attached as Exhibit&nbsp;99.1 to this Current Report on
Form 8-K. </TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD align="left">PolyMedix, Inc. issued a press release on December&nbsp;10, 2008
announcing Phase I clinical data for PMX-30063. The press release is attached
as Exhibit&nbsp;99.2 to this Current Report on Form 8-K.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD align="left">In accordance with
General Instruction B.2 of Form 8-K, the information in this Current Report on
Form 8-K, including Exhibit 99.1 and Exhibit&nbsp;99.2, shall not be deemed
&#8220;filed&#8221; for the purposes of Section&nbsp;18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, except as shall be expressly set
forth by specific reference in such a filing. The information in this Report
will not be deemed as an admission as to the materiality of any information
required to be disclosed solely to satisfy the requirements of
Regulation&nbsp;FD. </TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

 <TR valign="bottom">
  <TD valign="top" align="left"><B>Item&nbsp;9.</B><B>01(d)</B></TD>
  <TD align="left"><B> Financial Statements and Exhibits.</B></TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD align="left"> 99.1 Slideshow presented on December&nbsp;10, 2008 at PolyMedix,
Inc.&#8217;s special meeting of stockholders. The slide presentation is
furnished and not filed pursuant to Instruction&nbsp;B.2 of Form&nbsp;8-K. </TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD align="left">99.2 Press release issued December&nbsp;10, 2008 by PolyMedix, Inc. The press
release is furnished and not filed pursuant to Instruction B.2 of Form 8-K. </TD>
</TR>
</TABLE>
</DIV>



<P style="font-size: 10pt" align="left"><B>Forward-Looking Statements</B>

<P style="font-size: 10pt" align="left"><I>This Current Report on </I><I>Form
8-K</I><I>, including Exhibit&nbsp;99.1 and Exhibit&nbsp;99.2 attached hereto,
contains forward-looking statements made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995 that involve risks and
that could cause PolyMedix&#8217;s actual results and experience to differ
materially from anticipated results and expectations expressed in these forward
looking statements.&nbsp; PolyMedix has tried, wherever possible, to identify
these forward-looking statements by using words such as
&#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;hopes,&#8221;
&#8220;estimates,&#8221; &#8220;looks,&#8221; &#8220;expects,&#8221;
&#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;goal,&#8221;
&#8220;potential,&#8221; and similar expressions.&nbsp; Among other things,
there can be no assurance that PolyMedix&#8217;s compounds will enter or
successfully complete clinical testing or be granted regulatory approval to be
sold and marketed in the Unites States or elsewhere. &nbsp;A more complete
description of these risks, uncertainties and assumptions is described under
the heading &#8220;Risk Factors&#8221; in PolyMedix&#8217;s filings with the
Securities and Exchange Commission. You should not place undue reliance on any
forward-looking statements.&nbsp; PolyMedix undertakes no obligation to release
publicly the results of any revisions to any such forward-looking statements
that may be made to reflect events or circumstances after the date of this
Current Report or to reflect the occurrence of unanticipated events, except as
required by applicable law or regulation.</I>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>SIGNATURE</B>

<P style="font-size: 10pt" align="left">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="50%">&nbsp;</TD>
  <TD width="50%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD valign="top" align="left">POLYMEDIX, INC.</TD>
 </TR>

<TR><TD>&nbsp;</TD></TR>

 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">December&nbsp;10, 2008 </DIV>
</TD>
  <TD valign="top" align="left" style="border-bottom: 1px solid #000000">/s/ Edward F. Smith</TD>
 </TR>

 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD valign="top" align="left">Edward F. Smith</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD valign="top" align="left">Vice President, Finance and Chief Financial
Officer</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><U><B>Exhibit&nbsp;Index</B></U>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD nowrap align="left"><B>Exhibit No.</B></TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">99.1 Slideshow presented on December&nbsp;10,
2008 at PolyMedix, Inc.&#8217;s special meeting of stockholders.</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.2 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">99.2 Press release issued December&nbsp;10,
2008 by PolyMedix, Inc.</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c78138e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 11881}]
{"company-data": {"conformed-name": "POLYMEDIX INC", "cik": "0001341843", "assigned-sic": "2834", "irs-number": "000000000", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51895", "film-number": "081240000"}, "business-address": {"street1": "C/O POLYMEDIX INC", "street2": "3701 MARKET STREET STE 442", "city": "PHILADELPHIA", "state": "PA", "zip": "19104", "phone": "2159666199"}, "mail-address": {"street1": "C/O POLYMEDIX INC", "street2": "3701 MARKET STREET STE 442", "city": "PHILADELPHIA", "state": "PA", "zip": "19104"}, "former-company": {"former-conformed-name": "BTHC II ACQUISITION CORP", "date-changed": "20051019"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): December 10, 2008
POLYMEDIX, INC.
(Exact name of registrant as specified in its charter)
Delaware
000-51895
27-0125925
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
170 N. Radnor Chester Road,
Suite 300
Radnor, Pennsylvania
19087
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
(448) 598-2400
Not
Applicable
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01.
Regulation FD Disclosure.
On December 10, 2008, PolyMedix, Inc. presented a slide
presentation at its special meeting of stockholders entitled
"Presentation of Phase IA PMX-30063 Clinical Results". A copy of
the presentation is attached as Exhibit 99.1 to this Current Report on
Form 8-K.
PolyMedix, Inc. issued a press release on December 10, 2008
announcing Phase I clinical data for PMX-30063. The press release is attached
as Exhibit 99.2 to this Current Report on Form 8-K.
In accordance with
General Instruction B.2 of Form 8-K, the information in this Current Report on
Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed
"filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, except as shall be expressly set
forth by specific reference in such a filing. The information in this Report
will not be deemed as an admission as to the materiality of any information
required to be disclosed solely to satisfy the requirements of
Regulation FD.
Item 9.
01(d)
Financial Statements and Exhibits.
99.1 Slideshow presented on December 10, 2008 at PolyMedix,
Inc.'s special meeting of stockholders. The slide presentation is
furnished and not filed pursuant to Instruction B.2 of Form 8-K.
99.2 Press release issued December 10, 2008 by PolyMedix, Inc. The press
release is furnished and not filed pursuant to Instruction B.2 of Form 8-K.
Forward-Looking Statements
This Current Report on
Form
8-K
, including Exhibit 99.1 and Exhibit 99.2 attached hereto,
contains forward-looking statements made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995 that involve risks and
that could cause PolyMedix's actual results and experience to differ
materially from anticipated results and expectations expressed in these forward
looking statements.  PolyMedix has tried, wherever possible, to identify
these forward-looking statements by using words such as
"anticipates," "believes," "hopes,"
"estimates," "looks," "expects,"
"plans," "intends," "goal,"
"potential," and similar expressions.  Among other things,
there can be no assurance that PolyMedix's compounds will enter or
successfully complete clinical testing or be granted regulatory approval to be
sold and marketed in the Unites States or elsewhere.  A more complete
description of these risks, uncertainties and assumptions is described under
the heading "Risk Factors" in PolyMedix's filings with the
Securities and Exchange Commission. You should not place undue reliance on any
forward-looking statements.  PolyMedix undertakes no obligation to release
publicly the results of any revisions to any such forward-looking statements
that may be made to reflect events or circumstances after the date of this
Current Report or to reflect the occurrence of unanticipated events, except as
required by applicable law or regulation.
SIGNATURE
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
POLYMEDIX, INC.
December 10, 2008
/s/ Edward F. Smith
Edward F. Smith
Vice President, Finance and Chief Financial
Officer
Exhibit Index
Exhibit No.
99.1
99.1 Slideshow presented on December 10,
2008 at PolyMedix, Inc.'s special meeting of stockholders.
99.2
99.2 Press release issued December 10,
2008 by PolyMedix, Inc.